Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered

R. Laniado-Laborín

DOI: https://doi.org/10.1586/ers.10.6

2010-04-01

Expert Review of Respiratory Medicine

Abstract:Despite global control efforts, drugresistant strains of Mycobacterium tuberculosis remain a public-health challenge, infecting millions of people worldwide [1]. Multidrug-resistant TB (MDR-TB), defined as TB resistant to at least isoniazid and rifampin, represents a serious obstacle to TB control, especially in areas where its prevalence is high [2]. The most recent estimates suggest that globally there were more than half a million cases of MDR-TB in 2007, of which fewer than 30,000 were notified to the WHO; this amounts to only 8.5% of the estimated global total of smear-positive cases of MDR-TB [3]. In an increasingly integrated world, these lethal TB strains do not stay at home for long. In the 1990s, a global surveillance project demonstrated that drug-resistant strains of M. tuberculosis were globally ubiquitous, and in several countries were sufficiently common as to potentially threaten control programs [4]. Globally, cases of MDR-TB are unevenly distributed; the prevalence of drug-resistant TB is inversely correlated with the quality of TB control programs, with the most important factor being improper use of firstand second-line anti-TB drugs [5]. Multidrug-resistant TB development is also attributable to inadequate laboratory diagnosis and unsupervised treatment. This is particularly the case in settings where limited resources restrict access to drug susceptibility testing (DST) and implementation of universal directly observed therapy (DOT), in which a trained healthcare worker monitors the patient’s taking of each and every dose of medication [1]. In most lowand middle-income countries, drug sensitivity testing is not performed for either new cases or for most patients requiring retreatment. Therefore, patients with undetected drug resistance will receive empiric standardized treatments with ineffective first-line drugs and, consequently, can be predicted to have a high probability of failure and relapse [6]. To address this problem, the WHO and the Stop TB Partnership have called for an expansion of DST of TB drugs [3]. Unfortunately, despite the increase in funding for global TB control that has occurred over the past decade, large funding gaps remain, making DST unfeasible in many countries, particularly in those with the highest rates of MDR-TB.